2.Cloning and Expression Analysis of two Endosperm Promoters in Rice
Yong-Lan CUI ; Xiao-Li ZHONG ; Yong-Ming ZHANG ; Zhong-Nan YANG ;
China Biotechnology 2006;0(08):-
The cloning of promoter is important for studying the genetic engineering and the regulation of gene expression in plants. Two promoters Os772 and Os359, which are predicted to be highly expressed in the endosperm of rice from the EST database were cloned. After construction of the Os772∶∶GUS and Os359∶∶GUS expression vectors, they were transformed into rice. X-Gluc staining of transgenic plants showed that Os772 and Os359 can promote GUS gene expression in matured endosperm but not in root, stem, leaf and flower. This result indicates Os772 and Os359 are two rice endosperm-specific promoters.
3.Etiology of severe acute respiratory syndrome.
Chang-an ZHAO ; Zhong-zhi LI ; Yong-hong YANG
Chinese Journal of Pediatrics 2003;41(6):439-440
4.Effect of high glucose environment on the NF-κB/Iκ B signal pathway in cultured rat glomerular mesangial cell and its mechanism
Ling XU ; Jia LI ; Lan JIANG ; Yong XU ; Haihua ZHONG
Chinese Journal of Endocrinology and Metabolism 2010;26(2):152-154
To explore the effect of high glucose on the NF-κB/IκB signal pathway in cultured rat glomerular mesangial cells. The results showed that high glucose increased the degradation of IκB-α and the translocation to nucleus of NF-κB. These changes could be reverted mostly by MG132, a proteasome inhibitor. It suggests that the activation of the NF-κB signal pathway by high glucose concentration may probably be via the ubiquitin-proteasome pathway.
5.Relapse after hematopoietic stem cell transplantation: Report of two cases and review of literature
Qing LI ; Yaohui WU ; Zhaodong ZHONG ; Yong YOU ; Ping ZOU
Chinese Journal of Organ Transplantation 2013;(2):75-78
Objective To evaluate the effect of cytokine-induced killer cells (CIKs) as an adoptive immunotherapy option for treatment of leukemia relapse after allo-hematopoietic stem cell transplantation (allo-HSCT).Methods Two cases of infusion of donor CIKs in patients with leukemia relapse after allo-HSCT were retrospectively analyzed.Patient one relapsed 986 days (+986d) after HLA-matched unrelated donor allo-HSCT.Applications of chemotherapy only resulted in short term remission,but allo-CIKs were successfully expanded from the patient's peripheral blood mononuclear cells of donor origin.Totally five cycles of CIKs infusion were infused as an alternative of adoptive immunotherapy.Patient two had recurrent in the + 158d after HLA-matched sibling alloHSCT.At + 204d and + 294d,two cycles of CIKs which were expanded from donor peripheral blood mononuclear cells were infused.Results One cycle of CIKs was given to patient one after the application of chemotherapy to reduce the tumor burden,and the patient successively achieved complete remission.Again after additional four cycles of CIKs infusion,consistent remission was maintained during the following seven months.Patient two who had relapsed disease posttransplantation,achieved cytological complete remission after withdrawal of immunosuppressants and undergoing chemotherapy combined with G-CSF mobilized stem cell infusion.However,at + 187d,the patient suffered from side-effect of acute graft versus host disease and extramedullary infiltration.The symptoms were alleviated markedly after one cycle of CIKs infusion at + 204d.Moreover,the pain disappeared after an additional infusion at + 294d.And up to the present,the bone marrow aspiration showed complete remission while the extramedullary disease vanished.Conclusion The use of CIKs in the treatment of leukemia relapse after allogeneic bone marrow transplantation can be feasible and well tolerated.
6.Continuous intravenous infusion of midazolam for treatment of status epilepticus in children.
Jian-min ZHONG ; Jian-hua LI ; Yong CHEN
Chinese Journal of Pediatrics 2004;42(4):299-300
Adolescent
;
Age Factors
;
Anti-Anxiety Agents
;
administration & dosage
;
adverse effects
;
therapeutic use
;
Child
;
Child, Preschool
;
Female
;
Humans
;
Infant
;
Infusions, Intravenous
;
Male
;
Midazolam
;
administration & dosage
;
adverse effects
;
therapeutic use
;
Status Epilepticus
;
drug therapy
;
Treatment Outcome
Result Analysis
Print
Save
E-mail